Pfizer enters in vivo CAR-T with $2.6B Starna deal

  • <<
  • >>

Pfizer has entered the in vivo CAR-T space through an exclusive licensing agreement with China-based Starna Therapeutics covering three preclinical programs targeting autoimmune diseases.

The deal, which could reach $2.6 billion, marks Pfizer's first move into in vivo CAR-T development.

Under the agreement, Pfizer will pay Starna $330 million upfront, with the biotech eligible for up to $2.3 billion in additional development and commercial milestone payments, plus royalties on net sales of approved products.

Pfizer gains exclusive rights to develop, manufacture and commercialize the three pre-IND programs outside Greater China. The company will lead clinical development in those territories and plans to manufacture drug product for initial clinical trials at its U.S. facilities. Pfizer also holds options to expand its territorial rights to include Greater China.

The programs leverage Starna's proprietary RNA technology and targeted LNP delivery platform to generate CAR-T cells directly inside the body.

In addition to the three autoimmune programs, Pfizer secured rights to use Starna's in vivo CAR-T technology in inflammation and immunology and oncology, along with options to exclusively license compounds emerging from a separate research collaboration.

The agreement expands Pfizer's inflammation and immunology pipeline and adds another major pharmaceutical company to the growing effort to apply CAR-T approaches to autoimmune diseases. Eli Lilly has also made significant investments in the field, including its acquisitions of Kelonia Therapeutics and Orna Therapeutics in 2026.

 

Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox! Sign up now!

More news